CRISPR Technology Market: Pending Patent Issues & Results Of Clinical Trials
Summary
- The CRISPR technology market is expected to grow from USD 562 million in 2018 to USD 1,715 million by 2023, at a CAGR of 25% during the forecast period.
The CRISPR technology market is expected to grow from USD 562 million in 2018 to USD 1,715 million by 2023, at a CAGR of 25% during the forecast period.
The major factors driving the CRISPR technology market include the rising funding from government and private organizations and the high adoption of CRISPR technology.
The CRISPR products segment is expected to command the largest share of the CRISPR technology market during the forecast period.
The CRISPR Products Market, by product and service, is estimated to be dominated by the products segment in 2018. This is attributed to the fact that the CRISPR technology is being adopted quickly by academics and researchers, pharma and biotech companies. The enzymes segment is expected to account for the largest share of the products market, being one of the key ingredients in the CRISPR process.
Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134401204
Biomedical applications to occupy the majority of the market, by application, and grow at the fastest rate during the forecast period.
The biomedical applications segment is projected to be the fastest-growing segment of the CRISPR Products Market, by application, during the forecast period. Developments in gene therapy, drug discovery, and diagnostics, due to the application of CRISPR, are driving the growth of this biomedical segment. Many companies have also invested in drug discovery and gene therapy companies that are using CRISPR technology.
North America is estimated to account for the largest share of the CRISPR Products Market in 2018.
The large share of CRISPR technology in this region is majorly attributed to the rising government and private funding, presence of major pharma and gene therapy companies, and the adoption of CRISPR in a number of applications. Crops that are treated with CRISPR-based gene editing are not considered as GMOs in the US, which has attracted the attention of agricultural companies to the commercialization of CRISPR-edited crops.
Request a Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=134401204
Leading Companies
Some of the key players of CRISPR in this region are Cellecta, Inc. (US), Thermo Fisher (US), GeneCopoeia, Inc. (US), Applied StemCell (US), Synthego Corporation (US), OriGene Technologies (US), Horizon Discovery (UK), Merck (Germany), and GenScript (US).
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.